Markets
ABT

Abbott: Study Shows HeartMate 3 Pump Extends Life Expectancy Of Advanced Heart Failure Patients

August 29, 2022 — 09:19 am EDT

Written by RTTNews.com for RTTNews->

(RTTNews) - Abbott (ABT) said the data from the MOMENTUM 3 trial showed its HeartMate 3 heart pump extended survival of advanced heart failure patients by at least five years. Results of the five-year study showed an improved survival rate of 58% with the HeartMate 3 compared to 44% with the HeartMate II. Also, the greater survival for HeartMate 3 patients was largely associated with a reduction in deaths due to stroke, clotting and bleeding.

The company also noted that the latest MOMENTUM 3 data showed that the five-year survival for HeartMate 3 patients is approaching the five-year survival rates of heart transplant recipients who have a similar risk profile.

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source->

Stocks mentioned

ABT

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.